Approaches for optimizing biomarker profiling using liquid chromatography tandem mass spectrometry by Suhr, Anna Catharina
Dissertation 
zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität München 
 
 
 
 
Approaches for optimizing biomarker profiling using 
liquid chromatography tandem mass spectrometry 
 
 
 
 
Anna Catharina Suhr 
Melle 
 
2017 
  
 
 
Aus dem Institut für Laboratoriumsmedizin 
der Ludwig-Maximilians-Universität München 
 
Direktor: Univ.-Prof. Dr. med. Daniel Teupser 
 
 
 
 
 
Approaches for optimizing biomarker profiling using 
liquid chromatography tandem mass spectrometry 
 
 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
vorgelegt von 
Anna Catharina Suhr 
aus 
Melle 
 
2017 
  
 
 
Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
 
 
Berichterstatter:   Prof. Dr. med. Michael Vogeser 
 
 
Mitberichterstatter:   PD Dr. med. Dr. rer. nat. Harald Mückter 
    Prof. Dr. med. Oliver Peschel 
    PD Dr. rer. nat. Elisabeth Deindl 
 
 
 
 
 
 
Dekan:    Prof. Dr. med. dent. Reinhard Hickel 
 
 
Tag der mündlichen Prüfung: 29.06.2017 
 
  
 
 
Eidesstattliche Versicherung 
 
Suhr, Anna Catharina 
 
Ich erkläre hiermit an Eides statt,  
dass ich die vorliegende Dissertation mit dem Thema  
 
“Approaches for optimizing biomarker profiling using liquid chromatography tandem mass 
spectrometry“  
 
selbstständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich 
gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe.  
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher Form 
bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde.  
 
 
München, den 27.09.2016 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Kumulative Dissertation 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keep calm and mass spec on. 
 
 
 
 
 
  
 
 
TABLE OF CONTENTS 
1. Introduction .......................................................................................................... 1 
1.1. Background ................................................................................................... 1 
1.1.1. Definition ................................................................................................. 1 
1.1.2. Metabolomics and biomarker discovery .................................................. 1 
1.1.3. Biomarker profiling in clinical diagnostics ................................................ 3 
1.1.4. Challenges of LC-MS/MS assays ........................................................... 4 
1.1.5. Aim and Scope ........................................................................................ 6 
1.2. Development of a validation experiment for surrogate matrix calibrated 
LC-MS/MS biomarker assays ................................................................................. 7 
1.3. Evaluation of ferromagnetic particles based deproteination as suitable 
sample preparation technique for demanding endogenous biomarker panels ........ 8 
1.4. Summaries .................................................................................................. 10 
2. Original Articles ................................................................................................. 12 
2.1. Suhr, A. C., Vogeser M., Grimm, S. H. Isotope Inversion Experiment 
evaluating the suitability of calibration in surrogate matrix for quantification via 
LC-MS/MS – Exemplary application for a steroid multi-method. J Pharm Biomed 
Anal 2016; 124:309-18 .......................................................................................... 12 
2.2. Suhr A. C., Bruegel, M., Maier, B., Holdt, L. M., Kleinhempel, A., Teupser, D., 
Grimm, S. H., Vogeser, M. Ferromagnetic particles as a rapid and robust sample 
preparation for the absolute quantification of seven eicosanoids in human plasma 
by UHPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2016, 
1022:173-182 ........................................................................................................ 13 
3. Appendix ........................................................................................................... 14 
3.1. List of abbreviations ..................................................................................... 14 
3.2. References .................................................................................................. 15 
3.3. Publications ................................................................................................. 17 
3.4. Acknowledgement ....................................................................................... 19 
 
1 
 
1. INTRODUCTION 
1.1. Background 
1.1.1. Definition 
Biological markers, or biomarkers, play an important role in nearly all medical 
disciplines since they are ‘objective indications of medical state observed from 
outside the patient – which can be measured accurately and reproducibly,’ as 
described by Strimbu and Tavel [1]. 
As objective medical indicators, biomarkers are used in screening procedures (e.g. 
blood glucose to assess patient risk of diabetes mellitus), diagnosis (e.g. troponin to 
evaluate suspected myocardial infarction) and patient follow-up (e.g. prostate-specific 
antigen to determine the success of therapy against prostate cancer). 
Biomarkers can take very different forms, including small molecules, 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, whole cells, 
measurements of physiological functions (e.g. blood pressure), histologic specimens 
and imaging [1]. Moreover, in addition to medical science, biomarkers play an 
important role in other life sciences. 
1.1.2. Metabolomics and biomarker discovery  
The discovery of new biomarkers to better diagnose disease states has long been 
important to clinical researchers. The critical challenge in this field of research is how 
to identify promising biomarker candidates. 
Recently, technical advances in analytics and informatics have enabled the 
emergence of the so-called ‘-omics’ disciplines: genomics (DNA), transcriptomics 
(RNA), proteomics (proteins) and metabolomics (metabolites). Based on their 
comprehensive approaches, all four have huge potential for the discovery of new 
biomarkers [2].  
Since changes due to disease or environmental conditions are usually well reflected 
by alterations in cell metabolite patterns, the metabolomics discipline is of particular 
importance in the search for new biomarkers. Consequently, in this study, the main 
focus is on small molecules and their potential to serve as biomarkers.  
The two strategies for biomarker discovery depend on the information currently 
available regarding the pathogenesis of a given disease: untargeted hypothesis-free 
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metabolomics and targeted metabolomics, which are based on previously known 
facts. Both strategies can result in a set of interesting metabolites [3]. 
This predefined set is then quantified for two sample groups – patients and healthy 
controls – and statistical analyses are performed to determine which analyte panel is 
most appropriate for differentiating these two groups. If a promising biomarker (panel) 
candidate is identified, it is validated in a clinical study with larger cohorts of patients 
and controls to assess its sensitivity and specificity as a diagnostic test [4]. 
Biomarker panels can be composed of both closely related compounds and, at the 
same time, compounds from a broad variety of chemical classes. Consequently, in 
metabolomics as well as in subsequent biomarker validation, there is a need for 
analytical techniques that are both capable of discriminating between very similar 
substances in one analytical run as well as facilitating the analysis of compounds with 
different physiochemical characteristics. Current techniques include nuclear magnetic 
resonance (NMR) spectroscopy, gas chromatography mass spectrometry (GC-MS) 
and liquid chromatography mass spectrometry (LC-MS) [5]. 
For various reasons that will be detailed below, an increasing number of publications 
in recent years indicate that LC-MS is the technique of choice in metabolomics [6]. 
Mass spectrometers identify previously ionized analytes by their mass-to-charge ratio 
(m/z). Depending on the type of mass spectrometer, they are either suited for 
identification and elucidating structure or for absolute quantification. 
When using tandem MS (MS/MS), analyte ions (precursor ion) are further fragmented 
into product ions. Since these product ions are somewhat specific to the structure of 
a molecule, selectivity is further enhanced by tandem MS such that more analytes 
(even those with the same precursor m/z) can be quantified in parallel. Since 
biomarker profiling is mainly based on the quantification of numerous analytes in one 
run, triple quadrupole tandem mass spectrometers (‘triple quads’) are widely used in 
biomarker profiling [5].  
The GC-MS and LC-MS techniques share the unique advantage of stable isotope 
dilution (SID), i.e. the application of stable isotope-labelled (SIL) analyte counterparts 
as internal standards. The analyte and the respective SIL internal standard have 
different masses (different m/z) but behave very much alike since they share nearly 
identical physicochemical properties. Hence, the use of SID allows for the correction 
of analyte loss during sample preparation as well as for the differing matrix effects of 
different samples. The so-called matrix effect describes the influence of co-eluting 
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matrix ingredients that suppress or enhance the ionization of the analyte. 
Furthermore, the use of SIL internal standards allows for the identification of chemical 
background peaks of interfering substances that are similar to those of the analyte 
[4]. As a consequence, SID clearly increases the robustness of assays with respect 
to the diversity of matrices of human samples in biomarker profiling. 
Frequently, analytes must be derivatized to make them detectable in GC-MS 
analysis, and this is especially so for non-volatile or thermolabile analytes. Since 
ionization in LC-MS takes place at ambient pressure and does not depend on high 
temperature, these compounds are much more accessible with LC-MS [4]. 
Additionally, LC is very versatile due to the availability of different types of stationary 
and mobile phases [3].  
 
1.1.3. Biomarker profiling in clinical diagnostics 
Parallel and selective quantification, as discussed above, becomes even more 
important if a whole panel is addressed rather than a single biomarker. A very good 
example of the use of biomarker panels for differential diagnosis is given by the work 
of Arlt et al. [7]. The authors used GC-MS to establish a panel of steroids in urine for 
detecting malignancy in adrenal tumours. If ‘by chance’ during a diagnostic imaging 
procedure for an unrelated clinical purpose an adrenal mass is discovered, 
differentiation between adrenocortical carcinoma and adrenocortical adenoma is 
difficult when relying only on imaging and tumour size alone; nor does histology 
always deliver a decisive result. Arlt et al. demonstrated the extraordinary sensitivity 
and specificity of a biomarker panel based on steroid metabolomics [7]. 
The group of Mapstone [8] used (un-)targeted lipidomics based on LC-MS/MS to 
search for biomarkers of Alzheimer’s disease (AD) in peripheral blood. The authors 
discovered a profile of ten metabolites that identify people who will experience the 
onset of AD (or mild cognitive impairment) within two to three years. This 
blood-derived metabolic profiling technique may be very helpful in the search for 
disease-modifying therapies for AD [8]. 
A third interesting example is the use of metabolic profiling to enable the early 
diagnosis of Parkinson’s disease before decisive clinical symptoms become 
apparent. Luan et al. were able to discriminate with quite high sensitivity and 
specificity between patients at early, mid and advanced disease states and those in 
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control groups by analysing a panel of 18 metabolites (among them e.g. amino acids, 
steroids) via MS techniques [9].  
As these examples demonstrate, diagnoses based on biomarker profiling - rather 
than only on one or two markers - are becoming more common. This may be 
especially true for diseases that have to date lacked the identification of any decisive 
medical parameters.  
Today, the majority of assays in laboratory medicine employ automated analysers 
based on techniques such as photometry and immunochemistry. However, these 
techniques are not generally applicable for the analysis of biomarker panels since 
they are capable of quantifying only one analyte at a time. Furthermore, 
immunoanalysers are vulnerable to interferences caused by cross-reactions with 
similar substances or heterophilic antibodies [10]. 
In contrast, as described above, LC-MS/MS techniques offer specific and parallel 
quantification. In addition, an assay can usually be developed quickly and individually 
since, unlike immunoanalysers, LC-MS/MS systems are accessible to laboratory 
personnel and also very versatile, as noted above. Reagents and consumables can 
also be ordered independently from commercial kits, which allow greater flexibility in 
respect of novel insights in clinical research [11, 12]. Consequently, the use of 
LC-MS/MS in laboratory medicine is expected to increase. 
1.1.4. Challenges of LC-MS/MS assays 
Despite these encouraging aspects, the employment of LC-MS/MS in biomarker 
profiling faces several challenges: There is a lack of authentic blank matrices (e.g. 
plasma, serum, urine, saliva) that are free of the biomarkers of interest. Since most of 
these biomarkers also occur in healthy people – at different concentration levels – 
hardly any analyte-free authentic matrices are available. This hampers the 
convenient preparation of calibrators and controls with defined amounts of analytes 
in an authentic matrix. Several techniques have been employed to deplete matrices 
of analytes (e.g. charcoal-stripped serum for steroid analysis), but these typically 
considerably affect the composition of the matrix. As a consequence, it is doubtful 
that the resulting artificial products accurately characterise the authentic matrix. 
Therefore, these depleted matrices must be assigned as surrogate matrices, which 
can also consist of solvents such as water or methanol or a solution of serum 
albumin. 
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Other strategies that can be employed for calibrating without an authentic blank 
matrix are standard addition or a calibration based on a surrogate analyte [13, 14]. 
However, the most widely employed approach is the use of a surrogate matrix for the 
preparation of calibrators and controls. 
In this context, SID plays a crucial role since the composition and resulting matrix 
effect of a surrogate matrix differs significantly from that of the authentic matrix of the 
unknown samples. Unfortunately, SIL counterparts are not always commercially 
available, especially not for endogenous compounds, which may be an issue with 
respect to accurate and robust quantification in biomarker profiling. 
Furthermore, regarding biomarkers, it is quite likely that isobaric compounds occur, 
possibly as other analytes in the panel, or as disturbances present in the matrix. 
Isobaric compounds not only share precursor ions with the same m/z, but also 
product ions with same m/z. Consequently, even MS/MS cannot discriminate 
between them. A chromatographic separation of potentially interfering isobaric 
compounds is of utmost importance in such cases [3, 6]. Additionally, selectivity can 
be enhanced by monitoring at least two different product ions per analyte. 
Another challenge is the lack of guidelines for assay development and validation of 
biomarkers as endogenous compounds, in contrast to the well-known guidelines for 
xenobiotica provided, for example, by the European Medicines Agency (EMA), the 
Food and Drug Administration (FDA), and the Clinical & Laboratory Standards 
Institute (CLSI) [15-17]. Thus, existing validation protocols are typically 
‘home-brewed,’ which clearly hampers the standardization and comparability of 
assay quality. Several authors have recommended ‘fit-for-purpose validation 
protocols’ for endogenous substances. In particular, these protocols address critical 
validation aspects for endogenous compounds, such as the measurement of matrix 
effects, the assessment of selectivity or the correct determination of the lower limit of 
quantification (see e.g. [13, 14, 18, 19]). Thus far, there is no consensus paper or 
compulsory guideline for validating biomarker assay methods. As such, if biomarker 
profiling is used as a diagnostic procedure, considerable difficulty arises concerning 
accreditation etc. 
As discussed above, the matrix effect from co-eluting compounds can hamper 
accurate quantification. This is an important issue in biomarker profiling since the 
individual composition of samples of human material can vary substantially. A 
carefully chosen sample preparation can help to reduce the number of disturbing 
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matrix compounds in the extract. Additionally, the sample preparation for biomarker 
panels must be suitable for a group of analytes with varying physicochemical 
properties. 
However, in contrast to fully-automated immunoanalysers, LC-MS/MS involves 
laborious sample preparation (batch mode), long run times per sample and complex 
instrument maintenance that requires specially trained personnel and limits sample 
throughput [20]. Recent advances such as the development of ultra-high 
performance liquid chromatography (UHPLC), the integration of online solid phase 
extraction (SPE) and two-dimensional LC into MS platforms, as well as sound 
progress in liquid handling systems, has reduced the required hands-on time and 
improved the routine applicability of LC-MS/MS in clinical laboratories. Additionally, 
the development of multiplexing has enabled a better occupancy rate of expensive 
mass spectrometers since, in this case, one MS instrument can provide read outs for 
several LC instruments with staggered analysis time slots [12]. However, completely 
automated LC-MS/MS analysers are as yet unavailable – and this is a general 
drawback for the wider use of LC-MS/MS in laboratory medicine.  
1.1.5. Aim and Scope 
The aim of this research project was to develop solutions to address some of the 
abovementioned challenges in LC-MS/MS biomarker profiling and to improve the 
potential for using biomarker profiling in routine laboratory medicine, i.e. in clinical 
diagnostics.  
In the first project, the lack of an authentic blank matrix – as a typical challenge 
arising in the development of methods for the quantification of endogenous 
compounds – was addressed. The goal was to fill a gap in the validation process for 
LC-MS/MS assays of biomarker panels which use a surrogate matrix for calibration. 
The objective in the second project was to develop and evaluate a novel, 
automatable sample preparation technique for demanding endogenous biomarker 
panels. 
In both projects, a key step was the development of LC-MS/MS assays for biomarker 
profiling of clinically relevant small lipophilic compounds, and these two multi-analyte 
assays served as representative applications. 
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1.2. Development of a validation experiment for surrogate 
matrix calibrated LC-MS/MS biomarker assays 
Although the use of SID should compensate for differences between the surrogate 
matrix used for calibration and the authentic matrix of the unknown samples (see 
section 1.1.2), for assay validation proof is needed regarding the suitability of the 
chosen surrogate matrix. Certified, i.e. metrologically traceable, controls or 
proficiency testing samples can be analysed to indirectly demonstrate the suitability 
of the surrogate matrix used as calibrators in the newly developed LC-MS/MS 
biomarker assays. 
Unfortunately, no such certified controls typically exist for new biomarker candidates. 
This is especially true when it comes to complex biomarker panels; they are hardly 
obtainable. Consequently, there is a need for a specific validation experiment to 
evaluate the suitability of a surrogate matrix for its use as a basis for creating 
calibrators. 
To make the authentic and surrogate matrices comparable, i.e. analyte-free, a SIL 
compound, not naturally occurring anywhere, was employed as the analyte, and the 
nonlabelled, endogenous compound was used as the internal standard. Since the 
roles of the analyte and its SIL analogue were inverted, we refer to the new validation 
experiment as the Isotope Inversion Experiment. 
This Isotope Inversion Experiment consists of two parts: in the first part, the SIL 
compound is spiked into both the authentic and surrogate matrices to create inverse 
calibrators. Then, the resulting inverse calibration curves in the authentic and 
surrogate matrices were compared with respect to their linear regression. 
In the second part of the experiment, Inverse Quality Controls were created in the 
authentic matrix and quantified by the inverse calibration curve established in the 
surrogate matrix. The calculated accuracy of these controls served as the decisive 
figure of merit for the whole Isotope Inversion Experiment, since this result reflects 
the circumstances of the Standard Assay, i.e. quantification of the unknown samples 
in the authentic matrix by a surrogate matrix calibration. 
As a proof-of-concept application, the Isotope Inversion Experiment was successfully 
integrated into the validation process of a LC-MS/MS assay for a corticosteroid 
biomarker panel (for details, see section 2.1). 
Thus, this newly developed validation experiment will be a valuable tool in the 
validation of LC-MS/MS methods for addressing new biomarkers (or panels) and has 
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the potential for facilitating the development of a specific validation protocol for 
LC-MS/MS biomarker assays. 
 
1.3. Evaluation of ferromagnetic particles based 
deproteination as suitable sample preparation technique for 
demanding endogenous biomarker panels 
Ferromagnetic particles are a very promising tool in analytics, since they can be 
handled as a suspension by pipetting but can also be manipulated by magnetic force 
so that they temporarily become a solid phase. Depending on their surface coating, 
these particles can be used for i) the extraction of analytes, ii) the removal of 
disturbing substances from a sample or iii) to deliver a reagent. These particles are 
widely used in immunoanalysers and play an important role in (automatic) nucleic 
acid extraction [21]. Since the handling of these particles requires no centrifugation, 
vacuum or pressure, they could also be a valuable tool for the convenient automation 
of sample preparation prior to LC-MS/MS analysis [22]. 
The second possible area of application for ferromagnetic particles mentioned above, 
i.e. the removal of interfering matrix components from human samples, involves a 
rather generic approach that is independent of the analyte’s chemistry. Thus, the 
employment of ferromagnetic particles for sample preparation of heterogeneous 
biomarker panels prior to LC-MS/MS analysis seems very promising. Eicosanoids 
represent one group of demanding biomarkers. The analysis of these arachidonic 
acid metabolites is quite challenging due to their low levels in human body fluids, 
their instability and the possibility of their artificial formation during/after blood 
sampling. Furthermore, this group of potential biomarkers is characterised by broad 
physicochemical variety and many isobaric compounds [23]. In general, LC-MS/MS 
biomarker assays that address eicosanoids usually employ offline SPE for sample 
preparation. On the one hand, this technique offers a selection of analytes and the 
opportunity to concentrate them, but it also involves multiple time-consuming steps 
and is difficult to automate. To overcome these obstacles, we decided to evaluate the 
applicability of ferromagnetic particle enhanced deproteination in combination with 
online SPE as a semi-automated sample preparation technique for a biomarker 
assay addressing this group of demanding analytes. The prerequisite for this 
evaluation was the establishment of a respective analytical method. For this purpose, 
an LC-MS/MS assay for seven exemplary eicosanoids was successfully developed 
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and a thorough validation involving precision, accuracy, matrix effect, ruggedness 
and stability experiments was performed. The validation results were very 
satisfactory overall (compare section 2.2). 
The results clearly demonstrate that ferromagnetic particle enhanced deproteination 
is a robust and automatable tool (in combination with online SPE), that is not only 
suitable for the LC-MS/MS analysis of xenobiotica but also for demanding biomarker 
panels.  
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1.4. Summaries 
Summary in English 
Due to its selectivity and versatility, liquid chromatography tandem mass 
spectrometry (LC-MS/MS) is a key technology in the analysis of complex biomarker 
panels. However, several issues hamper the significant advance of LC-MS/MS in 
routine laboratory medicine, e.g. limited automation possibilities and the lack of 
validation regulations and certified external controls. 
Solutions were developed and investigated to address some of these issues within 
the scope of this research project: In the first project, a novel validation experiment to 
address the suitability of a surrogate matrix for calibrators and controls was 
developed. The feasibility of this experiment could be successfully demonstrated in 
the validation of a previously established biomarker marker assay for six 
corticosteroids. Based on these results, a substantial gap could be filled in the 
validation process of LC-MS/MS assays for endogenous compounds. 
In the second project, ferromagnetic particle enhanced deproteination was evaluated 
as a potential automatable sample preparation technique for biomarker panels with a 
broad variety of physicochemical properties. As a demonstration application, an 
eicosanoid panel including arachidonic acid and six of its metabolites was selected. 
The validation results confirm that ferromagnetic particle enhanced deproteination in 
combination with online solid phase extraction is a suitable sample preparation 
technique for demanding biomarker panels. This generic and automatable sample 
preparation technique could represent an attractive and novel solution for LC-MS/MS 
assays for biomarker panels. 
In summary, the two subprojects of this doctoral thesis deliver valuable solutions to 
advance the use of biomarker profiling via LC-MS/MS in clinical diagnostics. 
 
Zusammenfassung - Summary in German 
Aufgrund ihrer hohen Selektivität und großen Vielseitigkeit nehmen 
Flüssigkeitschromatographie-Tandemmassenspektrometrie(LC-MS/MS)-Methoden 
eine Schlüsselrolle beim Biomarker-Profiling ein. Nichtsdestotrotz gestaltet sich die 
Verwendung dieser Technik in der labormedizinischen Routineanalytik bis heute 
kompliziert. Dies liegt unter anderem an dem noch recht geringen 
Automatisierungsgrad der LC-MS/MS, am Fehlen von offiziellen 
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Validierungsrichtlinien sowie der Schwierigkeit, zertifizierte externe Kontrollen für 
neue Biomarkerpanele zu bekommen. 
Im Rahmen dieser Doktorarbeit wurden Lösungen für einige der zuvor erwähnten 
Punkte erarbeitet: Das erste Projekt beinhaltete die Entwicklung eines neuen 
Validierungsexperiments um die tatsächliche Verwendbarkeit einer 
Surrogatmatrix-Kalibrierung für die Quantifizierung von nativen Realmatrix-Proben 
mit unbekanntem Gehalt zu testen. Dieses neue Experiment konnte erfolgreich in die 
Validierung eines ebenfalls neu entwickelten Biomarkerassays für sechs 
Corticosteroide eingebunden werden. Es ist hervorzuheben, dass dieses Experiment 
eine nennenswerte Lücke in der Validierung von LC-MS/MS Assays für endogene 
Substanzen schließt. 
Ziel des zweiten Projekts war es herauszufinden, ob Magnetpartikel basierte 
Proteindepletion als Probenvorbereitung für anspruchsvolle Biomarkerpanele, welche 
Analyten mit einer großen Bandbreite physiko-chemischer Eigenschaften umfassen, 
geeignet ist. Als exemplarische Anwendung diente ein selbst entwickelter LC-MS/MS 
Assay für sieben Eicosanoide. Im Rahmen einer umfassenden Validierung konnte 
gezeigt werden, dass Magnetpartikel – in Kombination mit einer 
Online-Festphasenextraktion – für die Probenvorbereitung solcher komplexen 
Biomarkerpanele sehr gut geeignet sind. Somit stellt diese Art der 
Probenvorbereitung eine breit anwendbare und zudem automatisierbare Option für 
LC-MS/MS Assays dar. 
Abschließend ist festzustellen, dass im Rahmen dieser Doktorarbeit wertvolle 
Lösungen entwickelt und erprobt wurden, um das LC-MS/MS basierte 
Biomarker-Profiling in der klinischen Diagnostik voran zu bringen. 
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3. APPENDIX 
3.1. List of abbreviations 
DNA deoxyribonucleic acid 
RNA ribonucleic acid 
NMR nuclear magnetic resonance 
GC gas chromatography 
MS mass spectrometry 
LC liquid chromatography 
SIL stable isotope labelled 
SID stable isotope dilution 
AD Alzheimer’s disease 
EMA European Medicines Agency 
FDA Food and Drug Administration 
CLSI Clinical & Laboratory Standards Institute 
UHPLC ultra-high performance liquid chromatography 
SPE solid phase extraction 
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